KREBSBIO
Krebs Biochemicals and Industries financials
- Market cap
- ₹127 Cr
- Sector
- Healthcare
What Krebs Biochemicals and Industries Limited does
Krebs Biochemicals & Industries manufactures active pharmaceutical ingredients (APIs) and pharmaceutical intermediates, with commercial production commenced in 1994. Its Unit-I plant at Nellore is currently manufacturing and selling an API, while Unit-II at Kasimkota (Vizag) has been shut since February 2025 under an Andhra Pradesh Pollution Control Board closure order. Much of its manufacturing is done on a loan-license/contract basis for promoter company Ipca Laboratories Limited, which sources APIs, intermediates and job-work manufacturing from Krebs's facilities.
Segments
- Active Pharmaceutical Ingredients (APIs)
- Contract / loan-license manufacturing
- Manufacturing units
- 2 (Unit-I Nellore; Unit-II Kasimkota/Vizag)
- Unit-II (Vizag) operational status
- Non-operational since 9 Feb 2025 (AP Pollution Control Board closure order)
- Commercial production commenced
- 1994
- Unit-II regulatory certification
- EDQM (Europe) accredited and certified
- Unit-I customer qualification
- Audited and approved as a qualified vendor by European customers
- Manufacturing model
- Loan-license / contract manufacturing for promoter Ipca Laboratories Ltd.
Quarterly results
Q1 FY27: revenue up 27.4%, net profit up 53.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13 | 11 | 6 | 5 | 4 −68% | 7 −37% | 7 +12% | 7 +27% |
| EBITDA | -3 | -5 | -5 | -2 | -3 −3% | 0 +106% | -1 +84% | 1 +139% |
| Net profit | -6 | -8 | -8 | -5 | -6 −7% | -3 +60% | -2 +72% | -2 +53% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −22.3% 1Y
1Y: ₹75.55 on 10 Sept 2025 → ₹58.72. High ₹79.96 (22 Sept 2025), low ₹39.75 (30 Mar 2026).
Financials, as filed
Revenue fell 31.4% a year over 2 years, FY24 to FY26. Operating margin narrowed to -23.0%.
| Year ending | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹50 Cr | ₹43 Cr | ₹24 Cr |
| Operating profit | ₹-9 Cr | ₹-15 Cr | ₹-5 Cr |
| Operating margin | -17.3% | -34.7% | -23.0% |
| Interest | ₹5 Cr | ₹6 Cr | ₹7 Cr |
| Depreciation | ₹7 Cr | ₹7 Cr | ₹6 Cr |
| Net profit | ₹-20 Cr | ₹-27 Cr | ₹-17 Cr |
| Net margin | -39.1% | -62.2% | -71.3% |
| Cash from operations | ₹2 Cr | ₹-8 Cr | ₹-2 Cr |
| Free cash flow | ₹-5 Cr | ₹-11 Cr | ₹-5 Cr |
| ROCE | -19.0% | -30.0% | -15.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹20 Cr | ₹22 Cr | ₹22 Cr | ₹22 Cr | ₹22 Cr | ₹22 Cr |
| Reserves | ₹-62 Cr | ₹-97 Cr | ₹-121 Cr | ₹-141 Cr | ₹-179 Cr | ₹-184 Cr |
| Borrowings | ₹111 Cr | ₹143 Cr | ₹183 Cr | ₹194 Cr | ₹219 Cr | ₹225 Cr |
| Other liabilities | ₹91 Cr | ₹122 Cr | ₹91 Cr | ₹104 Cr | ₹106 Cr | ₹101 Cr |
| Total liabilities | ₹159 Cr | ₹190 Cr | ₹175 Cr | ₹178 Cr | ₹168 Cr | ₹163 Cr |
| Fixed assets | ₹118 Cr | ₹139 Cr | ₹147 Cr | ₹150 Cr | ₹146 Cr | ₹142 Cr |
| Capital work in progress | ₹12 Cr | ₹8 Cr | ₹4 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹29 Cr | ₹43 Cr | ₹24 Cr | ₹26 Cr | ₹20 Cr | ₹20 Cr |
| Total assets | ₹159 Cr | ₹190 Cr | ₹175 Cr | ₹178 Cr | ₹168 Cr | ₹163 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
The ownership split has held steady since Jun 2025. The shareholder count shrank 7% to 8,521.
- Promoters
- 72.7%
- FIIs
- 0.5%
- Public
- 26.8%
Since Jun 2025
- Promoters 0.00 pp
- FIIs 0.00 pp
- Public 0.00 pp
How it drifted, 12 quarters
Ownership split by quarter, oldest first. Sep '23: Promoters 72.7%, FIIs 0.5%, Public 26.8%.Dec '23: Promoters 72.7%, FIIs 0.5%, Public 26.8%.Mar '24: Promoters 72.7%, FIIs 0.5%, Public 26.8%.Jun '24: Promoters 72.7%, FIIs 0.5%, Public 26.8%.Sep '24: Promoters 72.7%, FIIs 0.5%, Public 26.8%.Dec '24: Promoters 72.7%, FIIs 0.5%, Public 26.8%.Mar '25: Promoters 72.7%, FIIs 0.5%, Public 26.8%.Jun '25: Promoters 72.7%, FIIs 0.5%, Public 26.8%.Sep '25: Promoters 72.7%, FIIs 0.5%, Public 26.8%.Dec '25: Promoters 72.7%, FIIs 0.5%, Public 26.8%.Mar '26: Promoters 72.7%, FIIs 0.5%, Public 26.8%.Jun '26: Promoters 72.7%, FIIs 0.5%, Public 26.8%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Rajasekhar Guttikonda newly disclosed 1.86% held
- Guttikonda Vara Lakshmi newly disclosed 1.70% held
The same filing shows 0 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Krebs Biochemicals and Industries Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Ipca Laboratories Limited | 49.65% | unchanged |
| Hemalatha Ravi | 12.48% | unchanged |
| Avinash Ravi | 9.93% | unchanged |
| Sun Pharmaceutical Industries Limited | 4.81% | unchanged |
| Rajasekhar Guttikonda | 1.86% | newly disclosed |
| Guttikonda Vara Lakshmi | 1.70% | newly disclosed |
| Ajay Ravi | 0.52% | unchanged |
| Dr R T Ravi | 0.11% | unchanged |
| Aditya Ravi | 0.05% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Krebs Biochemicals and Industries Limited
Guides on how to read this kind of business and the numbers that matter.